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B L O O D D O N O R S A N D B L O O D C O L L E C T I O N
Intravenous iron isomaltoside improves
hemoglobin concentration and iron stores in female
iron-deficient blood donors: a randomized double-blind
placebo-controlled clinical trial
Mikkel Gybel-Brask,1 Jens Seeberg,1 Lars L. Thomsen,2,3 and P€ar I. Johansson1
BACKGROUND: This trial evaluated the efficacy and
safety of intravenous (IV) iron isomaltoside (Monofer) in
comparison with placebo in first-time female blood
donors.
STUDY DESIGN AND METHODS: The trial was a
prospective, double blind, placebo-controlled,
randomized, comparative, single-center trial of 85 first-
time female blood donors. The subjects were randomly
assigned 1:1 to either 1000 mg IV iron isomaltoside
infusion or placebo. The primary endpoint of the trial was
change in hemoglobin (Hb) from baseline to right before
the third blood donation.
RESULTS: The increase in Hb was significantly higher
for iron isomaltoside compared with placebo right before
both the second blood donation (p 5 0.0327) and the
third blood donation (primary endpoint, p < 0.0001).
Improvements in other iron-related variables (plasma
iron, plasma ferritin, transferrin saturation, and
reticulocyte count) in favor of iron isomaltoside were also
observed. The trial was not powered on patient-reported
outcomes. However, improvements in iron stores and Hb
levels after iron isomaltoside administration were
supported by the fact that several of the fatigue
symptoms scores showed numerical differences in favor
of iron isomaltoside. There were no differences in side
effects between the groups.
CONCLUSION: In iron-deficient female blood donors a
single IV iron isomaltoside administration resulted in an
improvement in Hb concentration and iron stores and
demonstrated a favorable safety profile comparable to
placebo.
B
lood donors undergo a progressive decline in
their iron reserves, which can lead to iron-
deficient erythropoiesis. The prevalence of iron
deficiency due to blood donation is significantly
higher in menstruating women than in men and increases
progressively as the frequency of donation increases.1
According to a Danish trial, 31.7% of premenopausal
female blood donors showed depleted iron reserves and
3.3% developed iron deficiency anemia.2 In Denmark,
female blood donors are deferred from blood donation if
their hemoglobin (Hb) level is less than 12.5 g/dL3 and it
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is estimated that approximately 40% of all deferrals are
due to low Hb levels and approximately 95% of those are
women with childbearing potential.4 This inevitably
results in reduced donation frequency or cessation of
donation if not managed with iron supplements.
In patients, treatment with oral iron is suboptimal
because of limited absorption, lack of adherence, and
intolerance—or insufficient when the iron need is high.5,6
Therefore, intravenous (IV) iron is considered more effec-
tive and better tolerated and improves quality of life to a
greater extent than oral iron in patients.6-8 IV iron has not
been evaluated in a healthy blood donor population.
Iron isomaltoside (Monofer, Pharmacosmos) is one of
the newer IV iron formulations available. Clinical efficacy
and safety data are available for iron isomaltoside adminis-
tered to different patients groups with or without anemia.9-
16 However, there is a need for clinical efficacy and safety
data within healthy women with iron deficiency without
anemia, which is, for example, observed in blood donors.
MATERIALS AND METHODS
Trial design
This prospective, double-blind, placebo-controlled, ran-
domized, comparative, single-center trial was conducted
in Denmark from June 2013 to December 2016 in female
first-time blood donors at the Section for Transfusion Med-
icine, Department of Clinical Immunology, Rigshospitalet,
Copenhagen University Hospital. The objectives of this trial
were to evaluate the efficacy and safety of IV iron isomalto-
side in comparison with placebo in first-time female blood
donors. The subjects attended four to five visits: first blood
donation (Visit 0), screening visit (Visit 1), baseline or treat-
ment visit (Day 0; Visit 2), voluntary exercise visit (Week 3;
Visit 2a), second blood donation (12 weeks from first blood
donation; Visit 3), and third blood donation (12 weeks from
second blood donation; Visit 4) during the 24-week trial
period. All assessments performed at each trial visit are
shown in Table S1 (available as supporting information in
the online version of this paper).
The trial protocol and other related documents were
approved by competent authorities and the local ethics
committee (The Committees on Health Research Ethics
for the Capital Region of Denmark, approval date June 13,
2012; Approval H-3-2012-039). The trial was conducted in
accordance with good clinical practice and the Declara-
tion of Helsinki. Informed consent was obtained in writing
before any trial-related activities. The trial is registered at
ClinicalTrials.gov (Identifier NCT01895231).
Participants
Women at least 18 years of age, who were first-time donors
and had a plasma ferritin (p-ferritin) concentration of less
than 60 ng/mL were considered eligible to participate in the
trial. Hb concentration was routinely measured in all donors
using an EDTA-anticoagulated predonation venous sample
analyzed on a hematology analyzer (Sysmex XE-2100D, Sys-
mex Corp.). P-ferritin was routinely measured in all first-time
donors using a predonation serum sample on an immunodi-
agnostic system (Vitros 3600 or Vitros 5600, Ortho Clinical
Diagnostics). Eligible donors were approached by telephone
within 2 weeks of their first blood donation. Donors willing
to participate were included after having signed the informed
consent form. The exclusion criteria were iron overload or
disturbances in utilization of iron (e.g., hemochromatosis
and hemosiderosis); known hypersensitivity to any exci-
pients in the investigational drug products; history of drug-
related allergies or severe asthma; decompensated liver cir-
rhosis and hepatitis (defined as alanine aminotransferase> 3
times upper limit of normal); active acute or chronic infec-
tions (assessed by clinical judgment supplied with white
blood cell counts and C-reactive protein); rheumatoid arthri-
tis with symptoms or signs of active inflammation; women
who were pregnant or nursing; participation in any other
clinical trial where the trial drug had not passed five half-lives
before the screening; untreated vitamin B12 or folate defi-
ciency; treatment with other IV or oral iron products, includ-
ing iron-containing multivitamins within 4 weeks before the
screening; treatment with erythropoietin within 4 weeks
before the screening; and any other medical condition that,
in the opinion of the investigator, might cause the subject to
be unsuitable for the completion of the trial or place the sub-
ject at potential risk from being in the trial. During the trial
commencement, inclusion criterion “p-ferritin< 30 mg/L”
was changed to “p-ferritin< 60 mg/L” since fewer women
than expected had a p-ferritin level of less than 30 mg/L and a
p-ferritin level of less than 60 mg/L was also the normal crite-
rion at the site for initiating iron treatment. Furthermore,
specific list of contraceptives required was changed to a
more general term “adequate contraception (e.g., intrauter-
ine devices, hormonal contraceptives, or double-barrier
method).” Thus, women using the double-barrier method or
who were sexually inactive could also be included.
Any concomitant medication or treatment deemed
necessary to provide adequate supportive care was
allowed throughout the trial except the erythropoiesis-
stimulating agent treatment and any iron supplementa-
tion other than investigational drug including iron-
containing multivitamins as this would influence the out-
come measures of the trial. During the trial, Hb concentra-
tion, complete hematology set, p-ferritin, p-vitamin B12,
serum folate, transferrin saturation (TSAT), plasma iron
(p-iron), serum phosphate, and routine biochemistry were
measured as routine clinical samples at one laboratory at
the Department of Clinical Biochemistry, Rigshospitalet.
Randomization and interventions
The enrolled subjects were randomly assigned 1:1 to
receive either iron isomaltoside or placebo (sodium
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chloride; Natriumklorid 9 mg/mL, Fresenius Kabi). Sub-
jects in the iron isomaltoside group (43 subjects) received
a single-IV-dose infusion of 1000 mg of iron isomaltoside
over at least 15 minutes. Subjects in the placebo group (42
subjects) received saline as a single-dose infusion of
100 mL over at least 15 minutes.
Permuted block randomization with a block size of 6
was used to randomize the subjects. The randomization
list was prepared centrally by a contract research organi-
zation, Max Neeman International Data Management
Center, using a validated computer program (Statistical
Analysis Software [SAS] 9.1.3, SAS Institute, Inc.) PROC
PLAN procedure. An interactive Web response system
method was used to randomize the eligible subjects to the
treatment groups. When the subject data had been
entered into the interactive Web response system, a
unique randomization number was generated for the sub-
ject, identifying which treatment the subject was allocated
to. The screening and enrollment of the subjects were per-
formed by the investigator at the site, whereas the enter-
ing of the subject data into the interactive Web response
system generating the randomization number was per-
formed by the trial nurse or trial coordinator.
Blinding
The trial was double-blinded and thus both the subjects
and the investigators were blinded. Randomization, prep-
aration, and connection of infusions were handled by per-
sonnel otherwise unrelated to the trial. To ensure that, the
infusion bags and all visible disposables were wrapped in
aluminum foil by the personnel unrelated to the trial. All
used material was removed by the same person without
revealing the infused fluid.
Objectives and endpoints
The primary objective of the trial was to evaluate the
effect of IV iron isomaltoside compared with placebo on
Hb. The secondary objectives were to evaluate the effect
of iron isomaltoside compared with placebo on tolerance
of three blood donations, other relevant iron-related bio-
chemical variables, fatigue, restless leg syndrome (RLS)
symptoms, exercise tolerance, and safety.
The primary endpoint was to compare the change in
Hb concentration from baseline to right before the third
blood donation in the two trial arms. The secondary effi-
cacy endpoints were to measure and compare the follow-
ing in the two trial arms: change in Hb concentrations from
baseline to right before second donation; number of sub-
jects who could not tolerate three donations due to Hb con-
centration below the limit of acceptance (12.5 g/dL in
women); change in concentrations of p-iron, p-ferritin,
TSAT, and reticulocyte count from baseline to 12 weeks
after first and second blood donations; change in fatigue
symptoms from baseline to 12 weeks after first and second
blood donations measured by the Fatigue Visual Numeric
Scale and five questions from the Fatigue Severity Scale;
change in RLS symptoms from baseline to 12 weeks after
first and second blood donations measured by the
Cambridge-Hopkins Restless Legs Syndrome question-
naire; change in exercise tolerance from baseline to 3 weeks
after baseline measured by a two-step test on a bike; and
safety (adverse events [AEs], vital signs, electrocardiogram,
serum phosphate, and hematology and biochemistry varia-
bles). All efficacy outcomes were tested for superiority
whereas safety outcomes were summarized descriptively.
Sample size
The sample size calculation used the following assumptions:
superiority analysis, normally distributed data, Type 1 error
of 5%, two-sided test, and power of 80%. The null hypothe-
sis was that no effect was present. With a sample size of 37
subjects per treatment group and an assumed standard
deviation (SD) in Hb level of 1.5 g/dL, the trial was able to
detect a difference of 1.0 g/dL in change in Hb concentra-
tion from baseline to right before the third blood donation.
Statistical analysis
The following data sets were used in the analysis (Fig. 1):
 Safety analysis set (n 5 82): The safety analysis set
included all the subjects who were randomly
assigned and received at least one dose of investi-
gational product.
 Full analysis set (FAS; n 5 80): The FAS included all
the subjects who were randomized into the trial,
received at least one dose of investigational product,
and had at least one postbaseline Hb assessment.
 Per protocol (PP; n 5 74): The PP population
included all the subjects in the FAS who did not
have any major protocol deviations.
The primary analyses were conducted on the FAS and
PP analysis set. The secondary analyses were conducted
on the FAS, and the safety analyses were conducted on
the safety population.
The primary efficacy analysis and all secondary effi-
cacy endpoints related to “change from baseline” were
performed using an analysis of covariance with treatment
as factor and baseline value as covariate. The number of
subjects who could not tolerate three blood donations
was compared between iron isomaltoside and placebo
treatment groups using a chi-square or Fisher’s Exact test.
Adverse events were coded by system organ class and
preferred term using the Medical Dictionary for Regula-
tory Activities (MedDRA), Version 19.1. All the safety data
were summarized descriptively.
All statistical analyses were performed using computer
software (SAS, Version 9.4, SAS Institute). All statistical tests
were carried out as two-sided on a 5% level of significance
and all confidence intervals (CIs) were 95% intervals.
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RESULTS
Subjects
A total of 107 subjects were screened from June 2013 to
June 2016 and 85 of these were randomized into the trial
(43 subjects in the iron isomaltoside group and 42 subjects
in the placebo group). Overall, discontinuation was slightly
higher in the placebo group (iron isomaltoside group, 7.0%
[3/43]; placebo group, 14.3% [6/42]). Details of subject dis-
position are summarized in Fig. 1. Subject demographics
and baseline characteristics are summarized in Table 1.
Exposure to iron
All 41 subjects exposed to iron isomaltoside received the
full dose of 1000 mg. Of the 41 subjects receiving placebo,
two subjects received slightly less than the planned infu-
sion volume (94 and 85%, respectively) due to technical
problems.
Efficacy results
Changes in Hb concentration
The primary endpoint of the trial was change in Hb con-
centration from baseline to right before the third blood
donation (Visit 4). The analysis was conducted on the FAS
(n 5 80) and PP (n 5 74) analysis set. The difference esti-
mate between the two treatments groups was 1.25 (95%
CI, 0.90-1.61; p < 0.0001) in favor of iron isomaltoside in
the FAS (p < 0.0001; Fig. 2, Table 2), and similar results
were shown in the PP analyses (p < 0.0001; Table 2).
Statistical analysis of the secondary endpoint, change
in Hb concentration from baseline to right before the sec-
ond blood donation (Visit 3) on the FAS (n 5 78), is pre-
sented in Table 2. The increase in Hb concentration was
significantly greater for iron isomaltoside compared with
placebo (difference estimate, 0.35; 95% CI, 0.03-0.68; p 5
0.0327). The number of subjects who could not tolerate
three blood donations due to Hb concentration below the
Fig. 1. Subject disposition.
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limit of acceptance of 12.5 g/dL did not differ significantly
between iron isomaltoside and placebo (14/41 [34.1%] vs.
16/39 [41.0%] of subjects; p 5 0.5252).
Changes in iron indices
There was a mean increase in p-iron, p-ferritin, and TSAT
in the iron isomaltoside group from baseline to right
before the second blood donation (Visit 3). There was also
an increase in p-iron and TSAT in the placebo group,
whereas p-ferritin remained essentially unchanged. The
observed increase was significantly higher in the iron iso-
maltoside group (p-iron, p 5 0.0310; p-ferritin, p <
0.0001; TSAT, p 5 0.0002; Table S2 [available as supporting
information in the online version of this paper]; Fig. 2).
Mean reticulocyte count decreased from baseline to right
before the second blood donation (Visit 3) in both treat-
ment groups, but the decrease was statistically signifi-
cantly less in the iron isomaltoside group (p 5 0.0219;
Table S2, Fig. 2). At the third blood donation (Visit 4), the
change from baseline observed for p-iron, p-ferritin, and
TSAT was significantly higher in the iron isomaltoside
group (p-iron, p 5 0.0002; p-ferritin, p < 0.0001; TSAT, p
< 0.0001; Table S2, Fig. 2).
Donor fatigue and exercise tolerance
Overall, the mean fatigue symptoms scores appeared to
decrease from baseline during the trial for both treat-
ment groups (by up to 27%). The only exception was the
Fatigue Severity Scale question “Fatigue interferes with
my work, family, or social life,” where the score
decreased during the trial in the iron isomaltoside group
(1.93, 1.78, and 1.82 at baseline, Visit 3, and Visit 4,
respectively) but increased in the placebo group (2.38,
2.69, and 2.29 at baseline, Visit 3, and Visit 4, respec-
tively; p 5 0.0164). For the Fatigue Visual Numeric Scale
score, the decrease from baseline to right before the sec-
ond blood donation (Visit 3) tended to be greater for
iron isomaltoside than for placebo (p 5 0.0747). Other-
wise, no significant treatment differences were seen with
respect to change in fatigue symptoms scores (Table S3,
available as supporting information in the online version
of this paper).
Only very few subjects reported probable or definite
presence of RLS in both treatment groups (two subjects
for iron isomaltoside and three subjects for placebo).
There were no relevant changes during the trial in the
number of subjects reporting probable or definite pres-
ence of RLS (data not shown).
TABLE 1. Subject demographics and baseline
characteristics
Treatment group
Statistics/category
Iron
isomaltoside
(n 5 43)
Placebo
(n 5 42)
Age (years)
Mean (6SD) 23.2 (3.75) 24.9 (6.01)
Median 23.0 23.0
Range 18-35 18-45
Ethnic origin, n (%)
Caucasian 43 (100.0) 41 (97.6)
Asian 1 (2.4)
Current smoker, n (%)
Yes 6 (14.0) 15 (35.7)
No 37 (86.0) 27 (64.3)
Weight (kg)
Mean (6SD) 63.2 (8.4) 64.2 (9.2)
Median 62.0 62.7
Range 51.2-89.4 52.0-92.0
Biochemistry at baseline,
mean (6SD)
Hb (g/dL) 12.3 (0.6) 12.4 (0.8)
TSAT (%) 15.2 (8.3) 14.1 (7.2)
Ferritin (ng/mL) 16.4 (6.5) 14.0 (6.1)
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Fig. 2. Changes in Hb, p-iron, p-ferritin, TSAT, and reticulo-
cyte count from baseline to right before the second and third
blood donations (mean 6 SE), FAS. Estimates (mean and 95%
CI) from a mixed model with repeated measures with treat-
ment and time as factors, treat 3 time interaction, and base-
line value as covariate. *p<0.05, **p 5 0.001 to 0.01,
***p<0.001. BD 5 blood donation.
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A total of 26 subjects treated with iron isomaltoside
and 28 receiving placebo performed an exercise tolerance
test. The workload and heart rate at the two steps of the
incremental bicycle exercise test appeared similar for the
two treatment groups and no significant treatment differ-
ences were observed (data not shown).
Safety
In the iron isomaltoside group, 54 treatment-emergent
AEs (TEAEs) were reported in 28 subjects (68.3% of sub-
jects), while in the placebo group, 78 TEAEs were reported
in 31 subjects (75.6% of subjects). The most frequently
reported TEAEs were nasopharyngitis (17.1 and 17.1% of
subjects in the iron isomaltoside and placebo groups,
respectively), headache (4.9 and 9.8%), dizziness (4.9 and
9.8%), and anemia (0.0 and 12.2%). Except for anemia,
which was only reported in the placebo group, no other
specific patterns were identified when comparing TEAEs
between iron isomaltoside and placebo groups.
The TEAEs were mild (78% in the iron isomaltoside
group and 73% in the placebo group) or moderate (22% in
the iron isomaltoside group and 27% in the placebo
group). No severe TEAEs were reported. The majority of
TEAEs were recovered/resolved or recovering/resolving at
the end of trial (85% in the iron isomaltoside group and
81% in the placebo group).
A total of three treatment-emergent serious AEs
(SAEs) occurred during the trial (two SAEs in two subjects
in the iron isomaltoside group and one SAE in the placebo
group). The two SAEs in the iron isomaltoside group were
one spontaneous abortion and one pregnancy, and the
SAE in the placebo group was a spontaneous abortion. All
three SAEs were moderate in severity and assessed by the
investigator not to be related to investigational product.
In the iron isomaltoside group, four TEAEs in four
subjects were assessed to be possibly related or related to
investigational product (influenza-like illness, infusion
site irritation, cystitis, and urticaria), while in the placebo
group, seven TEAEs in five subjects were assessed to
be possibly related to investigational product (dyspepsia,
vomiting, pain, arthralgia, headache, RLS, and
hypotension).
There was one subject (2%) in the iron isomaltoside
group with p-phosphate levels of less than 2 mg/dL at any
time. The subject had a p-phosphate level of 1.92 mg/dL
at the third blood donation. The event was assessed as
nonclinically significant and not reported as an AE. No rel-
evant changes were seen in any of the safety-related
hematology or biochemistry variables during the trial.
There were no mean differences in systolic or dia-
stolic blood pressure or in heart rate between iron isomal-
toside and placebo. All electrocardiograms were assessed
to be normal, and there were no abnormal clinically sig-
nificant findings in the physical examinations or safety
issues observed with safety laboratory variables.
DISCUSSION
The prevalence of iron deficiency among blood donors is
high.17 Iron deficiency may lead to an increased preva-
lence of fatigue; decreased physical endurance; and
impairments in attention, concentration, and other cogni-
tive functions,18-20 which reduces donation frequency and
in worst cases ceases donation. According to data from
the REDS-II donor centers, approximately 10% of all
donation attempts (17.7% women; 1.6% men) end in a
deferral due to a low Hb or hematocrit.17 The blood
donors need to be managed with iron supplements to
keep up with the blood losses, and by maintaining healthy
iron levels donors will be able to safely continue donating
thereby ensuring a robust blood supply.
In the Hemoglobin and Iron Recovery Study (HEIRS),
a randomized nonblinded clinical trial, low-dose iron sup-
plementation (37.5 mg of elemental iron daily) or no iron
was given for 24 weeks. Recovery of iron stores in all par-
ticipants who received iron supplements took a median of
76 days and for participants not taking iron, median
recovery time was longer than 168 days (p < 0.001). With-
out iron supplements, 67% of participants did not recover
iron stores by 168 days.21
However, it can be difficult to ensure adherence to
oral iron supplementation because of the gastrointestinal
side effects such as constipation. Furthermore, the
absorption of oral iron is limited, and therefore oral iron is
TABLE 2. Analysis of change in Hb concentration (g/dL) from baseline to right before the second and third blood
donations
Endpoint, analysis set (number of subjects)
Iron
isomaltoside
(Group A),
LS mean
Placebo
(Group B),
LS mean
Difference
estimates
(95% CI) p value
FAS
Second blood donation (Group A, 40; Group B, 38) 1.7116 1.3578 0.3538 (0.0300-0.6780) 0.0327
Third blood donation (Group A, 41; Group B, 39) 1.7912 0.5385 1.2527 (0.8979-1.6076) <0.0001
PP
Third blood donation (Group A, 36; Group B, 38) 1.8506 0.5452 1.3054 (0.9357-1.6751) <0.0001
LS mean 5 least square mean.
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not the optimal treatment when the iron need is high.
Instead IV iron may be a more efficient and convenient
treatment of blood donors, and this randomized, prospec-
tive, double-blind, parallel, comparative placebo-
controlled, single-center trial was planned to evaluate the
efficacy and safety of IV iron isomaltoside in comparison
with placebo in first-time female blood donors. Improve-
ments in both Hb and other iron-related biochemical vari-
ables (p-iron, p-ferritin, TSAT, and reticulocyte count)
were observed in the iron isomaltoside group compared
with placebo. The increase in Hb observed before the sec-
ond blood donation in the placebo group is most likely a
physiologic compensation of the blood loss. However,
between the second and third blood donations, Hb
decreases in the placebo group indicating that the iron
stores are depleted.
The improvements in Hb and iron stores did not lead
to greater completion rate of blood donations. Even
though the number of subjects who could not tolerate
three blood donations due to Hb concentration below the
limit of acceptance of 12.5 g/dL was numerically lower in
the iron isomaltoside group, the trial was not powered to
this endpoint and it did not reach significance.
The trial was not powered to patient-reported out-
comes. However, the improvements in iron stores and Hb
levels after IV iron isomaltoside administration compared
with placebo was supported by the fact that several of the
fatigue symptoms scores showed numerical differences in
favor of iron isomaltoside and the fatigue score for
“Fatigue interferes with my work, family, or social life”
decreased significantly in the iron isomaltoside group. No
significant differences were observed in RLS symptoms or
exercise tolerance.
Intravenous iron isomaltoside administration was
well tolerated with a safety profile similar to placebo.
Three SAEs occurred, which were all assessed by the
investigator not to be related to investigational product.
There was a numeric higher frequency of related TEAEs in
the placebo group supporting the fact that there were no
safety issues with iron isomaltoside. This trial also indi-
cates that hypophosphatemia with IV iron isomaltoside
treatment appears not to be a concern.
The use of IV medication in healthy donors could be
of ethical concern and donor preferences are unknown—
it is believed that many donors stop taking oral iron sup-
plementation due to unpleasant gastrointestinal side
effects, and these side effects would be eliminated with IV
iron. Although we believe that IV iron administration is
feasible in our blood donation facility, this might not be
the case everywhere. The price of IV iron isomaltoside is
somewhat higher than a course of oral iron supplementa-
tion, which should be weighed against the efficacy; this
should be investigated further.
We believe that the internal validity of the trial is
high, owing to the prospective double-blind, randomized,
and placebo-controlled design. Whether the results are
generalizable to the entire donor population is uncertain,
as we included only female, first-time donors. Further tri-
als including returning donors and male donors on a
larger scale are warranted. In conclusion, a single IV iron
isomaltoside administration resulted in an improvement
in Hb concentration and iron stores and demonstrated a
favorable safety profile comparable to placebo.
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